Why Do Pharma PRC/MRC Reviews Fail?
Most PRC and MRC review failures in healthcare exhibiting aren’t creative problems. They’re structural ones.
Reviews fail when exhibit designs reach legal and medical review without fair balance requirements built into the architecture, when digital tools can’t accommodate real-time compliance updates, and when the exhibit house and agency of record aren’t working from the same playbook.
Prevention starts with an exhibit partner who joins the process at the concept stage, not after the booth is already built.
What Are PRC and MRC Reviews and Why Do They Matter for Exhibit Teams?
For life science marketing teams, PRC and MRC reviews are critical checkpoints between a creative concept and the show floor.
The Promotional Review Committee (PRC) evaluates promotional materials for regulatory compliance. The Medical Review Committee (MRC) ensures scientific claims, clinical data, and product messaging meet medical and evidentiary standards.
In healthcare exhibiting, nearly every element of the environment may need review:
- Booth graphics
- Interactive experiences
- Digital touchpoints
- Data visualizations
- Video content
- Supporting materials
Whether a team is preparing for the RSNA Annual Meeting, HLTH Annual Meeting, AAO Annual Meeting, AUA Annual Meeting, or another major medical meeting, the timelines are tight, and the stakes are high.
And exhibit environments introduce a challenge many internal review systems weren’t originally built for: translating regulatory requirements into physical space.
A fair balance statement that works perfectly in a detail aid doesn’t automatically translate to a 20-foot booth wall. A compliant slide deck may require significant structural support to work within an interactive exhibit environment.
When those gaps aren’t addressed early, they surface during review, and that’s when timelines, budgets, and launch plans start feeling pressure.
The Top 3 Reasons PRC and MRC Reviews Fail
1. Fair Balance Isn’t Built Into the Architecture
Fair balance requirements are one of the most common sources of exhibit review failure.
The issue usually isn’t awareness. Most healthcare marketing teams understand fair balance requirements extremely well.
The problem is that fair balance is often treated as content to be added later rather than a design requirement that should shape the environment from the beginning.
When fair balance is retrofitted into an exhibit after the creative direction is already established, the results are predictable:
- Safety information becomes difficult to read
- Risk disclosures compete visually with core messaging
- Compliance requirements feel disconnected from the experience itself
Regulatory-ready exhibit design approaches a fair balance architecturally through content hierarchy, spatial planning, viewing distance, surface placement, and exhibit flow.
When compliance is considered early, creativity and regulation stop competing with each other. And review teams aren’t encountering major issues for the first time late in the process.
2. Digital Tools Aren’t Built for Compliance Flexibility
Interactive digital experiences are now central to healthcare congress strategy.
Touchscreens, data explorers, HCP engagement tools, interactive kiosks, and dynamic content systems are everywhere on the healthcare show floor.
They’re also one of the biggest sources of review complications.
Many exhibit environments are built with fixed digital assets that become difficult to update once fabrication begins. But healthcare commercialization rarely stays static for long.
A label update, revised safety information, or new clinical data set can require changes quickly, sometimes between major medical meetings in the same calendar year.
When exhibit systems aren’t designed for flexibility:
- Review cycles get longer
- Launch windows tighten
- Update requests become expensive
- Teams scramble under time pressure
A more compliant exhibit environment is built, assuming change will happen.
That means:
- Digital systems that allow authorized updates
- Content structures designed for revision
- Exhibit architecture that can evolve alongside the science
Because what’s approved for one congress may need to shift before the next one.
3. Communication Gaps Between the AOR and Exhibit House
Most healthcare brands work with an agency of record (AOR) that manages brand standards, campaign strategy, and core promotional materials.
The exhibit partner is then responsible for translating that strategy into a physical environment.
That relationship sounds straightforward in theory. In practice, it’s often where review problems begin.
AOR teams typically carry deep institutional knowledge around:
- Regulatory history
- Approved claims
- Prior review feedback
- Medical-legal sensitivities
- Creative boundaries that already work
When exhibit partners are brought in too late or operate independently from that context, misalignment happens quickly.
The AOR submits materials based on one interpretation. The exhibit environment reflects another. Internal review teams receive conflicting executions. Revision rounds multiply. Timelines compress.
A strong exhibit partner understands the brand’s regulatory history early enough to work within it, not against it.
The goal isn’t just coordination.
It’s true collaboration between creative, compliance, and experiential teams from the beginning.
What Does a “No Surprises” Workflow Look Like in
Healthcare Exhibiting?
In healthcare, “no surprises” is more than a nice idea; it’s operational protection.
For Exhibit Happy by Steelhead, a no-surprises process means nothing reaches PRC or MRC review that hasn’t already been carefully evaluated through a compliance lens.
That process starts long before fabrication.
The Pre-Review Audit
Before exhibit concepts ever reach internal legal or medical review, designs should already be evaluated against the compliance realities most likely to affect them.
That includes:
- Fair balance visibility
- Disclaimer hierarchy
- Claim placement
- Digital content structure
- Interactive flow
- Therapeutic-area sensitivities
- Congress-specific requirements
This isn’t a legal review, and it doesn’t replace internal regulatory teams.
It’s a proactive design review process intended to identify issues before they become expensive revision rounds later. Because once review comments arrive after fabrication starts, costs and stress rise quickly.
The earlier those concerns are identified, the smoother the process becomes for everyone involved.
Agency Collaboration That Actually Works
In healthcare exhibiting, strong agency collaboration matters enormously.
AOR teams have often spent months, sometimes years, developing compliant creative systems and navigating the review history behind a specific product or indication.
A good exhibit partner respects that work.
That means:
- Understanding approved claims
- Working within established creative frameworks
- Aligning with the AOR early
- Flagging potential compliance concerns proactively
- Helping preserve consistency between campaign and environment
When that collaboration works well, PRC and MRC teams see a cohesive experience rather than disconnected creative interpretations.
That’s better for:
- Timelines
- Internal approvals
- Launch readiness
- And everyone’s stress levels
How Does Regulatory Agility Connect to Financial Protection?
Compliance failures don’t just create operational problems; they create financial ones, too.
A design that fails PRC or MRC review after fabrication begins can trigger:
- Reprints
- Revised graphics
- Digital rebuilds
- Structural modifications
- Accelerated production timelines
In a traditional ownership model, those costs stack onto an already-purchased asset.
In a flexible access model, exhibit systems are designed to accommodate updates more efficiently from the start.
That flexibility becomes especially valuable in healthcare environments, where regulatory updates, new data, and messaging shifts are expected as part of commercialization.
For life science marketing teams balancing compliance pressure with financial accountability, regulatory agility becomes more than operational convenience.
It becomes risk management.
Where Exhibit Happy by Steelhead Comes In
Healthcare exhibiting operates under a different level of pressure than most industries.
The science is complex. The review environment is strict. Timelines are compressed. And every congress appearance carries real visibility for both the brand and the product.
Exhibit Happy by Steelhead works with life science marketing teams to build compliant exhibit environments from the very beginning, integrating fair balance requirements, supporting agency collaboration, and creating exhibit systems designed for regulatory flexibility.
Because in healthcare, the best exhibit experience isn’t just the most visually impressive one.
It’s the one that clears review smoothly, reaches the floor on time, and allows the science to stand out the way it should.
Frequently Asked Questions
What is the difference between PRC and MRC review for exhibits?
PRC (Promotional Review Committee) evaluates exhibit materials for promotional and regulatory compliance. MRC (Medical Review Committee) evaluates scientific accuracy, clinical data presentation, and medical claim substantiation.
Most healthcare exhibit materials go through both processes.
When should an exhibit partner get involved in the PRC/MRC process?
Ideally, at the concept stage, before exhibit directions are finalized and long before fabrication begins.
The earlier exhibit teams understand compliance realities, the fewer late-stage revisions typically occur.
What is a fair balance in healthcare exhibit design?
Fair balance requires presenting safety and risk information clearly alongside promotional claims.
In exhibit environments, fair balance should be integrated into the design architecture itself rather than added after the creative direction is complete.
Why do digital exhibit tools create compliance challenges?
Because healthcare messaging changes frequently. Digital systems that can’t accommodate updates efficiently often lead to delays, revision costs, and increased review complexity.
What happens when the AOR and exhibit house aren’t aligned?
Review cycles typically become longer and more complicated. Misalignment between creative partners is one of the most common and most preventable sources of healthcare exhibit review failure.
Sources:
- U.S. Food and Drug Administration, Basics of Drug Ads — https://www.fda.gov/drugs/prescription-drug-advertising/basics-drug-ads
- U.S. Food and Drug Administration, OPDP Frequently Asked Questions — https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/opdp-frequently-asked-questions-faqs
- RSNA Annual Meeting — https://www.rsna.org/annual-meeting
- HLTH Annual Meeting (USA) — https://hlth.com/events/usa
- AAO Annual Meeting (American Academy of Ophthalmology) — https://www.aao.org/annual-meeting
- AUA Annual Meeting (American Urological Association) — https://www.auanet.org/about-us/industry-support-opportunities/aua-annual-meeting